2020
DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.
Klempner S, Bendell J, Villaflor V, Tenner L, Stein S, Naik G, Sirard C, Kagey M, Chaney M, Strickler J. DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival. Journal Of Clinical Oncology 2020, 38: 357-357. DOI: 10.1200/jco.2020.38.4_suppl.357.Peer-Reviewed Original ResearchProgression-free survivalDisease control rateObjective response ratePD-L1 expressionAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaDKN-01Overall survivalDKK1 expressionGEA patientsMedian progression-free survivalImmune-suppressive tumor microenvironmentPhase 1b/2a studyKaplan-Meier methodSuppressive tumor microenvironmentPotential predictive biomarkersPredictors of responseDKK1 mRNA expressionDKK1 antibodyMedian OSFree survivalClinical benefitSurvival outcomesControl ratePredictive biomarkers
2018
The effect of socioeconomic factors on the outcome of hepatocellular carcinoma.
Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.Peer-Reviewed Original ResearchMedian overall survivalCancer-directed treatmentOverall survivalHepatocellular carcinomaPrivate insurancePrimary insuranceInner-city tertiary care hospitalDecreased median overall survivalCox proportional hazard modelingMultivariate Cox proportional analysisCox proportional analysisTertiary care hospitalOS of patientsKaplan-Meier curvesProportional hazard modelingSocioeconomic factorsMedian OSSurvival benefitCare hospitalConsecutive patientsAJCC stageCancer RegistryMean ageTreatment courseSurvival advantage